The Customs Tariff Commission of the State Council of China has announced that beginning in 2026, the country will start to lower import duties on certain products. Levies will be lowered on resource-based commodities, including black ⁠powder for ‌lithium-ion batteries, as well as certain medical products, including artificial blood vessels and diagnostic kits for certain infectious ‌disease. For a total of 925 products, provisional import tariff rates will be lower than most-favoured-nation ⁠ra

Hyderabad: India ’s biotech nology sector is at a decisive crossroads. Long recognised as the pharmacy of the world and a dominant supplier of vaccines, the country is now attempting a far more complex transition, moving from scale-led manufacturing to innovation-led biotech leadership. At a recent high-level panel discussion during the maiden edition of ETPharma’s Biotech Symposium, industry leaders and experts discussed how India has built a strong foundation. They agreed the next phase will d

Axsome Therapeutics secured FDA priority review for its Alzheimer's disease agitation contender, despite a Phase III programme that served up a mixed bag of clinical results. The news was enough to send company shares up more than 19% on Wednesday.The US regulator accepted Axsome's supplemental application for AXS-05, which combines dextromethorphan and bupropion, and has set a decision deadline of April 30. The same active ingredients are already approved as Auvelity for major depressive disord

Vanda Pharmaceuticals is ending the year on a high note, securing FDA approval of its oral NK-1 receptor antagonist Nereus (tradipitant) to prevent vomiting induced by motion, with a market launch anticipated in the coming months."For the first time in over 40 years, patients have access to a novel therapy grounded in modern neuropharmacology, offering effective prevention without the limitations of existing options," remarked Mihael Polymeropoulos, chief executive of Vanda.The approval, announc

AbbVie is deepening its push into immuno-oncology with a deal that could reach $1.2 billion, securing global rights outside China to ZG006 (alveltamig), a trispecific T-cell engager developed by China's Suzhou Zelgen Biopharmaceuticals.The financial package includes $100 million upfront for Zelgen, as well as up to $60 million in near-term clinical and option-related payments. If AbbVie exercises its license option and the drug advances successfully, Zelgen stands to collect up to $1.075 billion

Corcept Therapeutics' bid to bring its cortisol-modulating drug relacorilant to patients with hypercortisolism suffered a setback after the FDA issued a complete response letter (CRL) rejecting the company's application. The news sent its stock down more than 50% on Wednesday.While the FDA acknowledged that Corcept's pivotal GRACE trial had met its primary endpoint and that confirmatory data from the Phase III GRADIENT study supported the filing, the regulator "concluded it could not arrive at a

TEMPE, Ariz., Dec. 30, 2025 /PRNewswire/ -- Nootropics Depot announced the publication of a new technical white paper titled " The Bioactive Imperative: Why Standardization to Unique Compounds is Essential for Botanical Product Integrity," authored by President and CEO Paul Eftang. The paper outlines how current quality practices in the botanical supplement sector can fail to ensure that finished products contain meaningful levels of pharmacologically active compounds, despite meeting identity a

Purity Products® is a leading nutritional supplement company founded in 1993 by President and CEO Jahn Levin, built on a passion for science and a commitment to wellness. What began as a small three-person operation in Great Neck, NY has grown into a thriving organization with over 100 employees and more than 200 evidence-based formulations serving over one million customers. Rooted decades of research and ingredient development, MyBladder® features UROX® — an award-winning, proprietary herbal b

RIYADH, SAUDI ARABIA, December 30, 2025 / EINPresswire.com / -- At King Faisal Specialist Hospital & Research Centre (KFSHRC), the treatment of drug-resistant epilepsy has developed over decades into a comprehensive clinical program that combines advanced diagnostics with tailored surgical intervention. Since the early 1990s, the hospital’s Epilepsy Centre has managed thousands of patients whose seizures did not respond to medication. Over time, this experience supported the performance of more

SHANGHAI, Dec. 30, 2025 /PRNewswire/ -- Insilico Medicine (03696.HK), a global leader in AI-driven drug discovery and a portfolio company of Qiming Venture Partners, today successfully listed on the Hong Kong Stock Exchange (HKEX). The listing marks the largest biotech IPO on the Hong Kong stock market in 2025. With an issue price of HK$ 24.05 per share, Insilico Medicine opened at HK$35.00 per share, representing a market capitalization of approximately HK$ 19.51 billion. Qiming Venture Partner